MedTech’s Quiet Consolidation: Why Devices Are Becoming a Platform Business
Medical device M&A is on pace for its most active year in the industry’s history, and the deal logic driving it is not simple scale — it is a defensive scramble to build AI capability and “GLP-1-proof” product portfolios before the next disruption arrives.
A Historic Pace
Medical device M&A activity bottomed out around $39 billion in 2023, rebounded to roughly $68 billion in 2024, surged past $80 billion in 2025, and the first quarter of 2026 alone exceeded $40 billion in announced transactions — a pace that puts the full year on track for somewhere between $80 and $100 billion, among the most active years the industry has ever recorded. That trajectory — a clean, multi-year acceleration rather than a single spike — is itself informative: it suggests a genuine structural shift in how device companies are approaching portfolio strategy, not a one-off reaction to any single event or opportunistic valuation window.
Abbott’s roughly $23 billion acquisition of Exact Sciences, maker of the Cologuard colorectal cancer screening test, and Boston Scientific’s $14.5 billion purchase of Penumbra, expanding its neurovascular and interventional thrombectomy portfolio, anchor a deal environment that spans essentially every major device category simultaneously, from diagnostics to cardiovascular to neurovascular intervention.
Trading EBITDA for Growth
The pattern beneath the headline numbers is not simply “big companies getting bigger.” Large device conglomerates are actively divesting profitable but slow-growing divisions — orthopedics, dental, diagnostics, and respiratory have all faced genuine growth headwinds in recent years despite remaining profitable businesses in their own right — specifically to concentrate capital on higher-growth categories, cardiovascular chief among them.
Industry consultancy ZS has described this succinctly as the industry “trading pure EBITDA for top-line velocity,” a barbell strategy where large consolidation plays in high-growth categories are deliberately balanced against targeted, smaller technology acquisitions aimed at securing specific future capabilities rather than simply adding revenue. That barbell framing is a useful lens for reading almost any individual 2026 deal announcement: the large, headline-grabbing acquisitions tend to sit at one end, consolidating an already-attractive growth category, while a steady stream of smaller, less publicized tuck-in acquisitions sit at the other, each aimed at a specific, narrow technology gap rather than a broad category play.
Cardiovascular’s Center of Gravity
Cardiovascular devices sit at the clear center of gravity for 2025-2026 deal capital, and the pattern across individual transactions is remarkably consistent: Boston Scientific’s Penumbra acquisition in neurovascular and interventional thrombectomy, Stryker’s $4.9 billion purchase of Inari Medical in peripheral vascular and venous thromboembolism treatment, Medtronic’s smaller but strategically pointed acquisitions of CathWorks for AI-based coronary diagnostics and Scientia Vascular for neurovascular access technology.
Strong, well-established reimbursement pathways combined with genuinely expanding indication sets and steady procedure-volume growth make cardiovascular the preferred investment thesis for both strategic acquirers and private equity sponsors right now, in a way few other device categories currently match — cardiovascular disease’s sheer prevalence across every major market, combined with decades of accumulated clinical evidence supporting device-based intervention, gives this category a reimbursement and procedure-volume stability that newer, less clinically established device categories simply cannot yet offer.
GLP-1-Proofing: The Defensive Logic Nobody Saw Coming
The most structurally interesting dynamic shaping 2026 dealmaking, and the one most directly relevant to this issue’s broader GLP-1 coverage, is what industry analysts have started calling “GLP-1-proofing.” The rapid, large-scale adoption of GLP-1 weight-loss drugs represents a genuine structural disruption threat to several medtech categories whose device utilization has historically correlated closely with obesity rates — sleep apnea devices, diabetes management technology, orthopedic implants tied to weight-related joint degeneration, and several cardiovascular intervention categories all face some version of this exposure.
Device companies are responding to that threat with M&A as much as with internal R&D, deliberately reshaping their portfolios to reduce dependency on obesity-linked device categories — not by resisting the pharmacological shift toward GLP-1 therapy, which by 2026 is clearly not a fight worth having, but by actively adapting their own product mix to the clinical landscape those drugs are creating. This is worth connecting directly to the retatrutide data discussed elsewhere in this issue: a drug demonstrating a 75.8 percent reduction in osteoarthritis pain scores is not an abstract pharmacology result to an orthopedic device maker — it is a direct forecast revision to a multi-billion-dollar joint-replacement and pain-management device market, and the companies moving fastest on GLP-1-proofing M&A are, in effect, pricing that forecast revision into their portfolio strategy today rather than waiting for the demand impact to show up in their own sales figures first.
AI as a Gating Item for Valuation
Artificial intelligence maturity has become, in the words of one 2026 industry analysis, “a gating item for valuation” rather than an optional growth lever — a meaningfully stronger statement than the more tentative “AI is increasingly important” framing that characterized industry commentary even a year or two earlier. Acquirers are using M&A specifically to secure AI and generative-AI capabilities rather than attempting to build them entirely in-house, and AI-enabled workflow platforms alongside healthcare data infrastructure are consistently cited as core M&A hotspots for 2026 specifically.
The broader industry is also visibly shifting business models, moving away from one-time capital equipment sales toward recurring-revenue structures — leasing and subscription models for expensive capital equipment, software-as-a-service layers monetizing analytics and AI on top of devices already installed in the field, and financing structures explicitly designed to match how outpatient and ambulatory surgical centers actually manage their operating budgets rather than how a traditional hospital capital-purchasing cycle works. That shift toward recurring revenue is itself a valuation-multiple story: a device business generating predictable, subscription-like recurring revenue commands a structurally higher multiple than an equivalent business dependent on lumpy, one-time capital equipment sales, which gives every device company a direct financial incentive to make exactly this transition regardless of what is happening in any specific therapeutic category.
The Capital Behind the Surge
Capital availability has been a genuine and specific catalyst behind the surge, not merely improving sentiment. Venture investment into medical device companies reached a record $10.4 billion in 2025, and median M&A deal values for private, venture-backed device companies climbed to $570 million for transactions with at least $50 million paid upfront — both figures reflecting a market that has moved decisively from capital preservation back into aggressive growth mode after the post-pandemic correction.
Debt markets have loosened and rates have drifted down, reviving the leveraged-buyout financing that private equity sponsors need to compete for scaled targets, while lower relative equity valuations following that correction have created what several dealmakers describe as a genuine window to strike before valuations reset upward again as the recovery matures further — a window that, based on the pace of 2026 dealmaking so far, appears to be closing faster than many participants initially expected, adding a genuine sense of urgency to the current wave of consolidation.
What This Means for a Venture-Stage Portfolio
For a healthcare venture fund, the medtech consolidation wave is less an area for direct large-scale investment — these are, almost by definition, later-stage, capital-intensive transactions well outside a typical venture check size — and more a critical signal for evaluating what a smaller, venture-stage medtech company’s eventual exit actually looks like.
A device company building genuine AI-enabled workflow capability, positioned in a growth category insulated from GLP-1 disruption risk rather than exposed to it, and structured around a recurring-revenue rather than one-time capital-sale business model, sits in exactly the profile the current wave of strategic acquirers is actively hunting for. That profile, more than any single feature in isolation, is increasingly what determines whether a venture-backed device company becomes an attractive acquisition target or gets left competing for a shrinking pool of buyers still running the older playbook — and it is the specific profile we now screen every medtech term sheet against, regardless of how compelling the underlying clinical technology looks in isolation.